MK-1775
|
- ₹0
- Product name: MK-1775
- CAS: 955365-80-7
- MF: C27H32N8O2
- MW: 500.6
- EINECS:
- MDL Number:MFCD17215200
- Synonyms:2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one;MK-1775;MK-1775,MK1775;2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one;2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one MK 1775;MK 1775 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one;MK-1775, >=98%;MK-1175
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Melting point :179-181°C
Boiling point :723.8±70.0 °C(Predicted)
Density :1.292
storage temp. :-20°C
solubility :Soluble in DMSO (70 mg/ml)
form :solid
pka :13.27±0.29(Predicted)
color :Yellow
Stability :Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChIKey :BKWJAKQVGHWELA-UHFFFAOYSA-N
SMILES :C1(NC2=CC=C(N3CCN(C)CC3)C=C2)=NC=C2C(=O)N(CC=C)N(C3=NC(C(O)(C)C)=CC=C3)C2=N1
Boiling point :723.8±70.0 °C(Predicted)
Density :1.292
storage temp. :-20°C
solubility :Soluble in DMSO (70 mg/ml)
form :solid
pka :13.27±0.29(Predicted)
color :Yellow
Stability :Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChIKey :BKWJAKQVGHWELA-UHFFFAOYSA-N
SMILES :C1(NC2=CC=C(N3CCN(C)CC3)C=C2)=NC=C2C(=O)N(CC=C)N(C3=NC(C(O)(C)C)=CC=C3)C2=N1
Safety Information
| Symbol(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|
Description
MK-1775 is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. MK-1775 is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow. MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.Related product price
- PD 0332991 HCl
₹12940 - Galeterone
₹11539.45-46547.5
